Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

INTRODUCTION: Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophag...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Medicine (Baltimore)
Prif Awduron: Mandrioli, Jessica, D’Amico, Roberto, Zucchi, Elisabetta, Gessani, Annalisa, Fini, Nicola, Fasano, Antonio, Caponnetto, Claudia, Chiò, Adriano, Dalla Bella, Eleonora, Lunetta, Christian, Mazzini, Letizia, Marinou, Kalliopi, Sorarù, Gianni, de Biasi, Sara, Lo Tartaro, Domenico, Pinti, Marcello, Cossarizza, Andrea
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer Health 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6024184/
https://ncbi.nlm.nih.gov/pubmed/29901635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011119
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg